If you or a loved one is taking Tysabri, understanding the testing and evaluation process for Progressive Multifocal Leukoencephalopathy (PML) is crucial. Medical research has long recognized the importance of balancing therapeutic benefits with potential risks, and this page provides clear, factual information on how PML is monitored and diagnosed.
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk. Clinical presentation and diagnosis of PML involve progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed through brain imaging, typically magnetic resonance imaging (MRI), and detection of JCV DNA in cerebrospinal fluid. In clinical trials, PML occurred in three patients who received Tysabri: two among 1,869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1,043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the latency between exposure and documented harm, which can range from months to years.
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system, which is beneficial for multiple sclerosis, but also impairs immune surveillance against JCV. The JC virus is latent in many individuals, and when immune control is compromised, it can reactivate and cause PML. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. Adequacy of warnings regarding Tysabri and PML is a central issue in litigation. The boxed warning explicitly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also mandates monitoring and immediate withholding of Tysabri at the first sign or symptom suggestive of PML. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed consent and risk mitigation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Despite these measures, lawsuits have been filed alleging that warnings were insufficient or that risks were not adequately communicated to patients and healthcare providers. Settlement-related considerations for affected patients involve several factors. The timeline between Tysabri exposure and PML diagnosis is critical, as longer treatment duration increases risk. Patients who develop PML may face severe disability or death, leading to substantial medical costs, lost income, and pain and suffering. Legal claims often focus on whether the manufacturer provided adequate warnings and whether the patient's specific risk factors (e.g., anti-JCV antibody status, prior immunosuppressant use) were properly assessed. Settlement criteria may include the duration of Tysabri use, the presence of other risk factors, the severity of PML outcomes, and the timing of diagnosis relative to treatment initiation. Patients who were not monitored according to guidelines or who developed PML despite negative anti-JCV antibody tests may have stronger claims. In summary, Tysabri-associated PML is a serious adverse event with a clear mechanistic basis and identifiable risk factors. The FDA boxed warning and TOUCH program represent regulatory efforts to mitigate risk, but litigation continues regarding the adequacy of these warnings. For affected patients, settlement considerations hinge on exposure duration, risk factor assessment, and the severity of harm. Healthcare providers and patients must remain vigilant for PML symptoms, as early detection and withholding of Tysabri are critical to improving outcomes.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a monoclonal antibody used for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Settlement criteria typically include duration of Tysabri use, presence of risk factors (e.g., anti-JCV antibody status), severity of PML outcomes, and timing of diagnosis. Patients not monitored per guidelines or who developed PML despite negative antibody tests may have stronger claims.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.